Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

Objectives The purpose of this study was to explore the efficacy and safety of toripalimab
combined with anlotinib in patients with advanced non‐small cell lung cancer (NSCLC) who …

Aim: A multicenter randomized phase III study designed to demonstrate non-inferiority of G
to E was conducted. Methods: Eligible pts were those with pathologically proven LA with …

Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …

A comment on this article appears in" Reply to G. Spitzer and MA Socinski, F. Zhou et al, and
B. Biswas." J Clin Oncol. 2015 Feb 10; 33 (5): 526-7. This is a comment on" Randomized …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

Results Median follow-up time was 71.9 wks. One pt was EGFR TKI naïve. Treatment-related
grade 3-4 adverse events (AEs) were reported in 5 pts (24%; increased AST [n= 2], diarrhea …

7104 Background: The mechanisms of resistance to EGFR tyrosine kinase inhibitors remain
poorly understood but may be related, in part, to dysregulation of downstream apoptotic …

Simple Summary The use of combination epidermal growth factor tyrosine kinase inhibitor
(EGFR-TKI) and immune checkpoint inhibitor (ICI) in EGFR-mutant, advanced non-small cell …

Purpose To evaluate the relationship between treatment efficacy and exposure of total and
unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal …